Leerink Partners analyst Danielle Antalffy maintained a Buy rating on Axonics Modulation Technologies (AXNX – Research Report) on January 24 and set a price target of $60.00. The company’s shares closed last Thursday at $54.29.
According to TipRanks.com, Antalffy is a 4-star analyst with an average return of 9.1% and a 52.0% success rate. Antalffy covers the Healthcare sector, focusing on stocks such as Inspire Medical Systems, Treace Medical Concepts, and Organogenesis Holdings.
Currently, the analyst consensus on Axonics Modulation Technologies is a Strong Buy with an average price target of $68.00.
The company has a one-year high of $79.81 and a one-year low of $42.37. Currently, Axonics Modulation Technologies has an average volume of 526.7K.
Based on the recent corporate insider activity of 30 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of AXNX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Axonics Modulation Technologies, Inc. operates as a medical technology company, which engages in the design, development, and commercialization of sacral neuromodulation solutions. The firm focuses on the treatment of patients with overactive bladder (OAB), fecal incontinence (FI), and urinary retention (UR). It offers rechargeable SNM system, which delivers mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of OAB, FI, and UR. The company was founded by Guang Qiang Jiang, Danny L. Dearen, Timothy Deer, and Michael V. Williamson in March 2012 and is headquartered in Irvine, CA.
Read More on AXNX:
- Robert W. Baird Sticks to Its Hold Rating for BWX Technologies (BWXT)
- Inari Medical (NARI) Receives a Buy from Leerink Partners
- Robert W. Baird Maintains Their Buy Rating on Textron (TXT)
- Albany International (AIN) Gets a Hold Rating from Robert W. Baird
- Robert W. Baird Believes Raytheon Technologies (RTX) Still Has Room to Grow